Review of teriflunomide and its potential in the treatment of multiple sclerosis

References

• WiendlHToykaKVRieckmannPBasic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendationsJ Neurol2008255101449146319005625
   PubMed Web of Science ®Google Scholar
• RansohoffRMNatalizumab for multiple sclerosisN Engl J Med2007356252622262917582072
   PubMed Web of Science ®Google Scholar
• RiceGPAHartungHCalabresiPAAnti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationaleNeurology20056481336134215851719
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med2006354991192316510745
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMastersBKTylerKLProgressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Engl J Med2005353436937415947079
   PubMed Web of Science ®Google Scholar
• Langer-GouldAAtlasSWGreenAJBollenAWPelletierDProgressive multifocal leukoencephalopathy in a patient treated with natalizumabN Engl J Med2005353437538115947078
   PubMed Web of Science ®Google Scholar
• Van AsscheGVan RanstMSciotRProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med20053534362815947080
   PubMed Web of Science ®Google Scholar
• HartungHNew cases of progressive multifocal leukoencephalopathy after treatment with natalizumabLancet Neurol200981283119081511
   PubMed Web of Science ®Google Scholar
• TYSABRI Update: Patients Treated with TYSABRI as of the end of December 2008. March 13, 2009. Accessed March 17, 2009. Available from: http://library.corporate-ir.net/library/14/148/148682/items/328677/D96A171A-3815-4766-940D-BE6E2DAD8F0A_biib-Tysabri13Mar09.pdf
   Google Scholar
• KranickSMMowryEMRosenfeldMRProgressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphomaNeurology200769770470617698796
   PubMed Web of Science ®Google Scholar
• MartinSIMartyFMFiumaraKInfectious complications associated with alemtuzumab use for lymphoproliferative disordersClin Infect Dis2006431162416758413
   PubMed Web of Science ®Google Scholar
• ColesAJCompstonDASSelmajKWAlemtuzumab vs. interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• KieseierBCWiendlHOral disease-modifying treatments for multiple sclerosis: the story so farCNS Drugs200721648350217521228
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• TallantyreEEvangelouNConstantinescuCSSpotlight on teriflunomideInt MS J2008152626818782502
   PubMedGoogle Scholar
• LiEKTamLTomlinsonBLeflunomide in the treatment of rheumatoid arthritisClin Ther200426444745915189743
   PubMed Web of Science ®Google Scholar
• MaddisonPKielyPKirkhamBLeflunomide in rheumatoid arthritis: recommendations through a process of consensusRheumatology (Oxford)200544328028615657072
   PubMed Web of Science ®Google Scholar
• OsiriMSheaBRobinsonVLeflunomide for treating rheumatoid arthritisCochrane Database Syst Rev20031CD00204712535423
   PubMed Web of Science ®Google Scholar
• RozmanBClinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators’ GroupJ Rheumatol Suppl19985327329666415
   PubMedGoogle Scholar
• BruneauJMYeaCMSpinella-JaegleSPurification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomideBiochem J1998336(Pt 2):2993039820804
   PubMed Web of Science ®Google Scholar
• FoxRIMechanism of action of leflunomide in rheumatoid arthritisJ Rheumatol Suppl19985320269666414
   PubMedGoogle Scholar
• FurstDELeflunomide, mycophenolic acid and matrix metalloproteinase inhibitorsRheumatology (Oxford)199938Suppl 2141810646484
   PubMed Web of Science ®Google Scholar
• GreeneSWatanabeKBraatz-TrulsonJLouLInhibition of dihydro-orotate dehydrogenase by the immunosuppressive agent leflunomideBiochem Pharmacol19955068618677575649
   PubMed Web of Science ®Google Scholar
• CherwinskiHMMcCarleyDSchatzmanRDevensBRansomJTThe immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanismJ Pharmacol Exp Ther199527214604687529314
   PubMed Web of Science ®Google Scholar
• FoxRIHerrmannMLFrangouCGMechanism of action for leflunomide in rheumatoid arthritisClin Immunol199993319820810600330
   PubMed Web of Science ®Google Scholar
• XuXWilliamsJWBremerEGFinneganAChongASInhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomideJ Biol Chem19952702112398124037759480
   PubMed Web of Science ®Google Scholar
• XuXBlinderLShenJIn vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr miceJ Immunol199715911671749200452
   PubMed Web of Science ®Google Scholar
• ZeydaMPoglitschMGeyereggerRDisruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formationArthritis Rheum20055292730273916142756
   PubMed Web of Science ®Google Scholar
• MannaSKAggarwalBBImmunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expressionJ Immunol19991624209521029973483
   PubMed Web of Science ®Google Scholar
• DéageVBurgerDDayerJMExposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metal-loproteinases-1 over that of interleukin-1beta and metalloproteinasesEur Cytokine Netw1998946636689889411
   PubMed Web of Science ®Google Scholar
• KraanMCReeceRJBargECModulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centersArthritis Rheum20004381820183010943872
   PubMed Web of Science ®Google Scholar
• BurgerDBegué-PastorNBenaventSThe active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytesRheumatology (Oxford)2003421899612509619
   PubMed Web of Science ®Google Scholar
• CaoWWKaoPNAokiYA novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2Transplant Proc1996286307930808962191
   PubMed Web of Science ®Google Scholar
• HamiltonLCVojnovicIWarnerTDA771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive mannerBr J Pharmacol199912771589159610455314
   PubMed Web of Science ®Google Scholar
• sanofi-aventis. ARAVA® Tablets (leflunomide) 10 mg, 20 mg, 100 mg. Prescribing information. July 2007. Accessed March 18, 2009. Available from: http://products.sanofi-aventis.us/arava/arava.pdf
   Google Scholar
• BeamanJMHackettLPLuxtonGIllettKFEffect of hemodialysis on leflunomide plasma concentrationsAnn Pharmacother2002361757711816264
   PubMed Web of Science ®Google Scholar
• KornTMagnusTToykaKJungSModulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletionJ Leukoc Biol200476595096015328336
   PubMed Web of Science ®Google Scholar
• MerrillJEHanakSPuSTeriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJ Neurol200925618910319169851
   PubMed Web of Science ®Google Scholar
• McFarlandHFMartinRMultiple sclerosis: a complicated picture of autoimmunityNat Immunol20078991391917712344
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLiDFreedmanMSA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology19833311144414526685237
   PubMed Web of Science ®Google Scholar
• PatyDWOgerJJKastrukoffLFMRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CTNeurology19883821801853340277
   PubMed Web of Science ®Google Scholar
• PoserCMPatyDWScheinbergLNew diagnostic criteria for multiple sclerosis: guidelines for research protocolsAnn Neurol19831332272316847134
   PubMed Web of Science ®Google Scholar
• MladenovicVDomljanZRozmanBSafety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II studyArthritis Rheum19953811159516037488280
   PubMed Web of Science ®Google Scholar
• SmolenJSKaldenJRScottDLEfficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study GroupLancet199935391492592669929017
   PubMed Web of Science ®Google Scholar
• StrandVCohenSSchiffMTreatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators GroupArch Intern Med1999159212542255010573044
   PubMed Web of Science ®Google Scholar
• van RielPLCMSmolenJSEmeryPLeflunomide: a manageable safety profileJ Rheumatol Suppl200471212415170904
   PubMedGoogle Scholar
• Aventis Pharmaceuticals. Important prescribing information. October 2003. Accessed March 18, 2009. Available from: http://www.fda.gov/medwatch/SAFETY/2003/arava_deardoc.pdf
   Google Scholar
• EmeryPBreedveldFCLemmelEMA comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritisRheumatology (Oxford)200039665566510888712
   PubMed Web of Science ®Google Scholar
• AuerJHinterreiterMAllingerSKirchgattererAKnoflachPSevere pancytopenia after leflunomide in rheumatoid arthritisActa Med Austriaca200027413113210989684
   PubMedGoogle Scholar
• HillRLToplissDJPurcellPMPancytopenia associated with leflunomide and methotrexateAnn Pharmacother200337114912503951
   PubMed Web of Science ®Google Scholar
• KaldenJRSchattenkirchnerMSörensenHThe efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up studyArthritis Rheum20034861513152012794818
   PubMed Web of Science ®Google Scholar
• JenksKAStampLKO’DonnellJLSavageRLChapmanPTLeflunomide-associated infections in rheumatoid arthritisJ Rheumatol200734112201220317937473
   PubMed Web of Science ®Google Scholar
• WarnatzKPeterHHSchumacherMInfectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literatureAnn Rheum Dis2003621505712480669
   PubMed Web of Science ®Google Scholar
• RozmanBPraprotnikSLogarDLeflunomide and hypertensionAnn Rheum Dis200261656756912006342
   PubMed Web of Science ®Google Scholar
• FukushimaRKanamoriSHirashibaMInhibiting the teratogenicity of the immuno-suppressant leflunomide in mice by supplementation of exogenous uridineToxicol Sci2009108241942619190124
   PubMed Web of Science ®Google Scholar
• FukushimaRKanamoriSHirashibaMCritical periods for the teratogenicity of immune-suppressant leflunomide in miceCongenit Anom (Kyoto)2009491202619243413
   PubMedGoogle Scholar
• FukushimaRKanamoriSHirashibaMTeratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor leflunomide in miceReprod Toxicol243–431031617604599
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health. Search for: teriflunomide multiple sclerosis - List Results - ClinicalTrials.gov. 2009Accessed March 18, 2009. Available from: http://clinicaltrials.gov/ct2/results?term=teriflunomide+multiple+sclerosis
   Google Scholar
• US National Institutes of Health. Search for relevant trials on: Home – ClinicalTrials.gov. 2009Accessed March 19, 2009. Available from: http://clinicaltrials.gov/
   Google Scholar
• KapposLAntelJComiGOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med2006355111124114016971719
   PubMed Web of Science ®Google Scholar
• PolmanCBarkhofFSandberg-WollheimMTreatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology200564698799115781813
   PubMed Web of Science ®Google Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837296481463147218970976
   PubMed Web of Science ®Google Scholar
• HofstetterHHStüveOHartungHIs 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunityExp Neurol200921714619254716
   PubMed Web of Science ®Google Scholar
• CurtisJRBeukelmanTOnofreiAElevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomideAnn Rheum Dis2009115[Epub ahead of print]
   Google Scholar